History and Achievements

Founded in 1992, Materia Medica Holding, a research and production company, developed its first original medications and launched their mass production quite soon after its establishment.

Video about the Company
1992 - 1999

By the end of the 1990s, the Company’s portfolio included more than 10 medicines of different pharmacological groups.

The Company’s products quickly gained the trust of doctors and patients.

1999

Phenomena of overdiluted solutions are discovered.

The Company conducts intensive multicenter clinical trials and develops a new class of medications based on ultralow doses of antibodies to endogenous regulators.

2000

The Company develops the first medication of a new class, Proproten-100.

The drug is intended for the treatment of alcohol addiction.

2002

The Company develops two medications: Anaferon and Anaferon for Children.

Both of these two medications are designed to treat and prevent flu and acute respiratory viral infections. Anaferon for Children is designed specifically for young children.

2003

The Company develops a medication called Impaza, which is designed for the treatment of erectile dysfunction.

2005

The Company develops Tenoten, a medication intended to relieve symptoms of anxiety and stress.

2006

The Company’s employees receive the Award of the Government of the Russian Federation in science and technology.

The prize was awarded for the development of a new class of medications based on ultralow doses of antibodies.

A medication called Afala has been developed. It is used for the treatment of prostate adenoma and chronic prostatitis.

2007

The Company opens new production shops and expands its own manufacturing facility in Chelyabinsk.

The factory is equipped with the most advanced manufacturing equipment of the world’s leading firms, which helps standardize the full cycle of the production of solid dosage forms.

2008

The Company develops a new medication, Tenoten for Children.

Tenoten for Children is the only sedative medicine created specifically for young children, taking into account the peculiarities of a child’s body.

The Company opens representative offices in Uzbekistan and Belarus.

2009

The Company receives U.S. patents for Anaferon and Afalaza.

The company opens a representative office in Kazakhstan.

2010

GMP approval.

The Federal Service for Surveillance in Healthcare and Social Development of the Russian Federation acknowledges that the manufacturing and quality control of medications by the Company are compliant with the requirements of OST 42-510-98 “Good Manufacturing Practice and Quality Control Rules for Medicinal Products (GMP)” and GOST R 52249-2009 “Good Manufacturing Practice and Quality Control Rules for Medicinal Products.”

2011

The Company develops an innovative antiviral medication, Ergoferon.

The drug has a complex mechanism of action and is used for the treatment of acute respiratory viral infections and influenza.

Materia Medica Holding opens a representative office in Southeast Asia.

2012

For ten years, pediatricians and mothers have put their trust in Anaferon for Children.

Anaferon for Children is recognized as the most frequently prescribed medicine for children*.


* According to COMCON-Pharma data for 2012.

GMP certificates are received.

The Company passes two EU GMP audits and receives two GMP certificates.

Brand of the Year No. 1 in Russia

The Anaferon brand is recognized as Brand of the Year No. 1 in Russia in the “Antiviral medications” category.


The Company becomes one of the leaders of the clinical trial market among Russian companies**.


** According to Synergy Research Group’s data for Q1 2013.

The Company develops a new medication called Brizantin. It is designed to alleviate the symptoms of smoking cessation.

2014

The Company opens an in-house research and development laboratory.

2015

The Company develops a new medication called Rengalin, intended for the treatment of dry and wet coughs.

The Company develops a medication called Divaza. The drug is intended for the treatment of chronic disorders of cerebral circulation.

Brand of the Year No. 1 in Russia

Yet again, the Anaferon brand becomes the winner of the Brand of the Year No. 1 prize in Russia, winning in the “Antiviral medications” category.

Expansion of the production facility

The Company opens a shop at its factory with a nominal capacity of up to one billion pills per year.

2016

The Company releases its new medication called Afalaza.

The drug is designed to address major male urological problems.

2017

Brand of the Year No. 1 in Russia

It is a third time that the Anaferon brand wins the Brand of the Year No. 1 prize in Russia, in the “Antiviral medications” category.

Best Employer

The Company is awarded the Best Employer status within the framework of the AON Best Employers Study 2017, a survey founded by AON Hewitt, a global HR consulting leader that conducts research in more than 90 countries worldwide.

2018

Platinum Ounce

Materia Medica Holding receives Platinum Ounce, one of the most prestigious awards of the Russian pharmaceutical community, in the category “Development of innovative medicines and their introduction into medical practice.”

Brand of the Year No. 1 in Russia

Rengalin is recognized as Brand of the Year No. 1 in the category of anticough medicines.

Green Cross

Rengalin receives Green Cross, a professional pharmacy award, winning in the “Best anticough medicine” category.

The Company develops a new veterinary medication, Anoten. The drug helps dogs and cats cope with anxiety and stress.

Leader in terms of the number of clinical trials and the number of patients enrolled

According to a Synergy Research report on clinical trials in Russia in Q3 2018, Materia Medica Holding, which initiated four new clinical trials (with 1,388 patients) in Q3 2018, was ahead of all domestic participants accounted for in the ranking in terms of the number of clinical trials. Moreover, the Company outranked international pharma manufacturers in the number of trial subjects.

2019

Recognition within the walls of the European Parliament

An international Russia—EU conference, “The Phenomenon of Release Activity: Prospects for Application in Medicine and Technology,” was held at the European Parliament building in Brussels. Leading experts from Russia, the U.S. and Europe confirmed the efficacy of medications based on ultrahigh dilutions for the treatment and prevention of various diseases.

GMP in the production of veterinary drugs

Materia Medica Holding receives a certificate of compliance with GMP requirements in the manufacturing of veterinary products.

Green Cross

The medication Afalaza receives Green Cross, beating out competitors among “Medications of choice for the early treatment of benign prostatic hyperplasia”.

Brand of the Year No. 1 in Russia

Ergoferon becomes Brand of the Year No. 1 in the category of antiviral medications.

2020

Green Cross

The medication Afalaza wins the Green Cross award again, beating out competitors among “Medications of choice for the early treatment of benign prostate hyperplasia.”


Ergoferon wins the Green Cross pharmacy award in the category “Medication of choice for the treatment of colds and flu”.

Brand of the Year No. 1 in Russia

Rengalin is awarded the Brand of the Year No. 1 prize as the best anticough medicine.

Product of the Year

The Anaferon brand wins the annual Product of the Year 2020 award in the “Consumer Confidence” nomination of the “Immunomodulators” category.

The medications Anaferon and Ergoferon are included into the Moscow Health Department’s manual with recommendations for the treatment and prevention of the coronavirus infection (COVID-19).

2021

The Company launches its first prescription medicine on the market. It is Prospecta®, an innovative medication, intended for the treatment of cognitive disorders of various origins, including those occurring in the wake of acute cerebral circulation disorders.

The Company develops a new innovative medication called Raphamin®. It is designed for the treatment of acute respiratory tract infections and prevention of bacterial complications. It exerts both antiviral and antibacterial activity.

Raphamin is a one-of-a-kind medicine that affects the molecules of the major histocompatibility complex (MHC), Class I and II. The MHC molecules are responsible for the recognition of viral and bacterial pathogens and participate in the activation of the immune response. As a result, Raphamin has not only an antiviral but also a moderately pronounced immune-mediated antibacterial effect. In the course of our research, a unique feature of the medication was experimentally proven: when Raphamin is used together with antibacterial medications, the efficacy of the antibiotic is enhanced even in case of initial resistance by pathogenic bacteria.

The developed combination of the Raphamin components is a fundamentally new solution in the treatment of acute respiratory tract infections.

Green Cross

Ergoferon wins in the category “Best antiviral medication.”


Tenoten is recognized as “The gold standard of therapy to achieve emotional tranquility.”

Brand of the Year No. 1

Ergoferon wins in the category “Best remedy for colds and influenza.”


Rengalin wins in the category “Best anticough therapy.”

Product of the Year

Rengalin wins the “Consumer Confidence” nomination in the category “Products used in the treatment of dry and wet coughs.”


Ergoferon is acclaimed as the best “Choice of specialists and consumers” in the category “Antiviral medications for acute respiratory infections and influenza.”

SmartPharma Awards

Impaza is crowned as the best remedy in the category “Medication for the treatment of erectile dysfunction”.

2022
Back to the top of the History section